Literature DB >> 20514016

Predicting the site of origin of tumors by a gene expression signature derived from normal tissues.

E Staub1, H-J Buhr, J Gröne.   

Abstract

Multiple expression signatures for the prediction of the site of origin of metastatic cancer of unknown primary origin (CUP) have been developed. Owing to their limited coverage of tumor types and suboptimal prediction accuracy on distinct tumors, there is still room for alternative CUP gene expression signatures. Whereas in past studies, CUP classifiers were trained solely on data from tumor samples, we now use expression patterns from normal tissues for classifier training. This approach potentially avoids pitfalls related to the representation of genetically heterogeneous tumor subtypes during classifier training. Two expression data sets of normal human tissues have been reanalyzed to derive an expression signature for liver, prostate, kidney, ovarian and lung tissues. In reciprocal validation, classifiers trained on either data set achieved overall accuracies greater than 97%. Classifiers trained on combined expression data from both normal tissue data sets were able to predict the site of origin in a cohort of 652 primary tumors with approximately 90% accuracy. Prediction accuracies of primary cancer-based classifiers were in the same range, as determined by cross-validation on this cohort. For individual tumor types, normal tissue-based classifiers achieved sensitivities in the range of 64-99% and specificities in the range of 92-100%. Primary origins for 12 of 20 metastases were predicted correctly, with false predictions highlighting the need for accurate sample preparation to avoid contaminations by metastases-surrounding tissue. We conclude that gene expression patterns of normal tissues harbor phenotypic information that is retained in tumors and can be sufficient to recover the type of primary tumor from expression patterns alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514016     DOI: 10.1038/onc.2010.196

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  4 in total

1.  Development and validation of a microRNA based diagnostic assay for primary tumor site classification of liver core biopsies.

Authors:  Katharina Perell; Martin Vincent; Ben Vainer; Bodil Laub Petersen; Birgitte Federspiel; Anne Kirstine Møller; Mette Madsen; Niels Richard Hansen; Lennart Friis-Hansen; Finn Cilius Nielsen; Gedske Daugaard
Journal:  Mol Oncol       Date:  2014-08-01       Impact factor: 6.603

2.  Classification of unknown primary tumors with a data-driven method based on a large microarray reference database.

Authors:  Kalle A Ojala; Sami K Kilpinen; Olli P Kallioniemi
Journal:  Genome Med       Date:  2011-10-17       Impact factor: 11.117

3.  Identification of the predictive genes for the response of colorectal cancer patients to FOLFOX therapy.

Authors:  Hengjun Lin; Xueke Qiu; Bo Zhang; Jichao Zhang
Journal:  Onco Targets Ther       Date:  2018-09-17       Impact factor: 4.147

4.  A Novel XGBoost Method to Identify Cancer Tissue-of-Origin Based on Copy Number Variations.

Authors:  Yulin Zhang; Tong Feng; Shudong Wang; Ruyi Dong; Jialiang Yang; Jionglong Su; Bo Wang
Journal:  Front Genet       Date:  2020-11-20       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.